| Study Name |
|
A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer |
| ClinicalTrials.gov Identifier (if applicable) |
|
NCT05211323 |
| Clinical Trial Category (check all that apply) |
|
|
| Study Center |
| Institution Name |
|
National Cancer Institute/ECOG-ACRIN Cancer Research Group |
| Institution Address |
|
5323 Harry Hines Blvd |
| City |
|
Dallas |
| State |
|
Texas |
| Zip Code |
|
75390 |
| Country |
|
United States |
| Study Contacts |
| Principal Investigator |
|
David Hsieh |
| P.I. Phone |
|
(214) 648-4180 |
| P.I. Email |
|
david.hsieh@UTSouthwestern.edu |
| Study Coordinator |
|
Ellen Siglinsky |
| Study Coordinator Phone |
|
(214) 645-9684 |
| Study Coordinator Email |
|
ellen.siglinsky@utsouthwestern.edu |
| OVERVIEW – in layman’s terms (150 words max) |
|
This phase II trial compares the effect of adding bevacizumab and atezolizumab to gemcitabine and cisplatin (chemotherapy) versus chemotherapy and atezolizumab in treating patients with combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA) that cannot be removed by surgery (unresectable) or that may have spread from where it first started. |
| Enrollment |
|
80 |
| Study Start Date |
|
01/27/2022 |
| Estimated Completion Date |
|
01/01/2025 |
| Financial Assistance is available to participants for travel, lodging, etc. |
|
|
